Publication Shows Utility of OGM in Solid Tumor Research with Study on Detection of Complex Genomic Rearrangements in Prostate Cancer
November 21 2022 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the
publication of a study utilizing optical genome mapping (OGM) to
detect structural variants (SVs) and balanced rearrangements
relevant to prostate cancer (PCa) pathogenesis. OGM identified SVs
in all samples, potentially improving the success rate for finding
pathogenic variants and streamlining the detection process.
In the study, published in Cancer Cell International,
researchers analyzed ten consecutive PCa samples to investigate
OGM’s ability to detect genomic aberrations and complex SVs which
may be associated with aggressive disease course and resistance to
androgen receptor-targeted therapies in solid tumor cancers. The
PCa genome is characterized by frequently balanced rearrangements
that affect multiple oncogenes and tumor suppressor genes. The
study reported that OGM helped identify alterations, deletions and
translocations which may cause or contribute to genomic instability
in cancer cells. The study authors highlighted challenges
associated with using traditional methods and cited OGM’s robust
detection of cryptic rearrangements with a high resolution as
evidence of its potential application as a first-line method in
solid tumor analysis.
“We have seen tremendous progress for the application of OGM in
constitutional genetic disorders. Within oncology research, several
prior publications have focused on blood or bone marrow analysis.
This paper serves as a good demonstration of OGM’s utility for
solid tumor research. The study authors demonstrate that OGM can be
more sensitive for detecting large structural variations and
balanced rearrangements than traditional methods or whole genome
sequencing. We believe this study provides a nice example of how
OGM can aid a sequencing-based approach to solid tumor molecular
assessment,” commented Erik Holmlin, PhD, president and chief
executive officer of Bionano Genomics.
This publication can be found here.
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also provides diagnostic testing
for patients with clinical presentations consistent with autism
spectrum disorder and other neurodevelopmental disabilities.
Through its BioDiscovery business, the Company also offers an
industry-leading, platform-agnostic software solution, which
integrates next-generation sequencing and microarray data designed
to provide analysis, visualization, interpretation and reporting of
copy number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. For more
information, visit www.bionanogenomics.com,
www.bionanolaboratories.com or www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “believe,” “can,” “may,” “potential,” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) convey
uncertainty of future events or outcomes and are intended to
identify these forward-looking statements. Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the ability and utility of OGM to detect SVs
and balanced rearrangements relevant to PCa pathogenesis; the
ability and utility of OGM to detect cryptic rearrangements when
compared to traditional methods; the ability and utility of OGM to
complement and aid sequence-based solid tumor molecular assessment.
Each of these forward-looking statements involves risks and
uncertainties. Actual results or developments may differ materially
from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: global and macroeconomic
events, such as the impact of the COVID-19 pandemic and the ongoing
Ukraine-Russian conflict and related sanctions, on our business and
the global economy; general market conditions; changes in the
competitive landscape and the introduction of competitive
technologies or improvements to existing technologies; failure of
OGM to achieve useful complementarity and aid sequence-based solid
tumor molecular assessment; failure of OGM to detect SVs and
balanced rearrangements relevant to PCa pathogenesis; failure of
OGM to detect cryptic rearrangements when compared to traditional
methods; future study results contradicting the results reported in
the publication referenced above; changes in our strategic and
commercial plans; our ability to obtain sufficient financing to
fund our strategic plans and commercialization efforts; the ability
of medical and research institutions to obtain funding to support
adoption or continued use of our technologies; and the risks and
uncertainties associated with our business and financial condition
in general, including the risks and uncertainties described in our
filings with the Securities and Exchange Commission, including,
without limitation, our Annual Report on Form 10-K for the year
ended December 31, 2021 and in other filings subsequently made by
us with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2023 to Apr 2024